Eli Lilly Japan Obtains Additional Approval for Gemzar Injection.Tokyo, Japan, July 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eli Lilly Japan announced o June 4 that it has obtained additional approval for Gemzar Injection (gemcitabine HC1), its proprietary anti-cancer agent, from the Ministry of Health, Labor and Welfare. The agent will now be available for the treatment of biliary tract cancer. Initially approved in Japan in March 1999, Gemzar is currently indicated for the treatments of non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. and pancreatic cancer pancreatic cancer Malignant tumour of the pancreas. Risk factors include smoking, a diet high in fat, exposure to certain industrial products, and diseases such as diabetes and chronic pancreatitis. Pancreatic cancer is more common in men. . The company expects that Gemzar, with its superior response rate and reduced side effects Side effects Effects of a proposed project on other parts of the firm. , will be an optimal choice for patients with biliary tract cancer. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion